{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T13:55:34Z","timestamp":1762610134465,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jdiacomp.2025.108977","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T19:33:03Z","timestamp":1739993583000},"page":"108977","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacological effect of ZYGK1, a novel glucokinase activator, in hyperglycemic and sulfonylurea-resistant type 2 diabetes in mice models"],"prefix":"10.1016","volume":"39","author":[{"given":"Kalpesh","family":"Patani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Joharapurkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Sundar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samadhan","family":"Kshirsagar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Metiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashutosh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mukul","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2025.108977_bb0005","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.mam.2018.11.001","article-title":"Endoplasmic reticulum stress and development of insulin resistance in adipose, skeletal, liver, and foetoplacental tissue in diabesity","volume":"66","author":"Villalobos-Labra","year":"2019","journal-title":"Mol Asp Med"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0010","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-024-01951-9","article-title":"Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy","volume":"9","author":"Lu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0015","first-page":"1","article-title":"Sedentary lifestyle and body composition in type 2 diabetes","volume":"14","author":"dan Li","year":"2022","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0020","doi-asserted-by":"crossref","unstructured":"Sarabu R, Bizzarro FT, Corbett WL, et al. Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients. J Med Chem 2012;55(16):7021\u20137036. doi:https:\/\/doi.org\/10.1021\/jm3008689.","DOI":"10.1021\/jm3008689"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000357332","article-title":"Sedentary behavior as a mediator of type 2 diabetes","volume":"60","author":"Hamilton","year":"2014","journal-title":"Med Sport Sci"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050215","article-title":"Why treatment fails in type 2 diabetes","volume":"5","author":"Rosengren","year":"2008","journal-title":"PLoS Med"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0035","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1517\/13543776.15.6.705","article-title":"Glucokinase: old enzyme, new target","volume":"15","author":"Kietzmann","year":"2005","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0040","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.2337\/diabetes.48.8.1645","article-title":"Characterization of glucokinase mutations associated with maturity-onset diabetes of the young type 2 (MODY-2): different glucokinase defects lead to a common phenotype","volume":"48","author":"Miller","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0045","doi-asserted-by":"crossref","unstructured":"Christesen HBT, Herold K, Noordam K, Gloyn AL. Glucokinase-Linked Hypoglycemia: Clinical Aspects of Activating Glucokinase Mutations. Glucokinase Glycemic Dis From Basics to Nov Ther. Published online December 2004:75\u201391. doi:https:\/\/doi.org\/10.1159\/000079008.","DOI":"10.1159\/000079008"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0050","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.2147\/DMSO.S186610","article-title":"Diagnosis and management of glucokinase monogenic diabetes in pregnancy: current perspectives","volume":"12","author":"Rudland","year":"2019","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0055","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1124\/mi.3.7.367","article-title":"Two birds with one stone: novel glucokinase activator stimulates glucose-induced pancreatic insulin secretion and augments hepatic glucose metabolism","volume":"3","author":"Al-Hasani","year":"2003","journal-title":"Mol Interv"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0060","doi-asserted-by":"crossref","first-page":"S236","DOI":"10.2337\/dc11-s236","article-title":"Glucokinase activators for diabetes therapy: may 2010 status report","volume":"34 Suppl 2(Suppl 2)","author":"Matschinsky","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0065","doi-asserted-by":"crossref","DOI":"10.1111\/j.1753-0407.2012.00193.x","article-title":"Exendin-4 ameliorates diabetic symptoms through activation of glucokinase","volume":"4","author":"Dhanesha","year":"2012","journal-title":"J Diabetes"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0070","doi-asserted-by":"crossref","first-page":"9314","DOI":"10.1016\/S0021-9258(18)31587-4","article-title":"Oscillations in cytosolic free Ca2+, oxygen consumption, and insulin secretion in glucose-stimulated rat pancreatic islets","volume":"266","author":"Longo","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0075","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/0003-9861(87)90648-5","article-title":"Factors underlying significant underestimations of glucokinase activity in crude liver extracts: physiological implications of higher cellular activity","volume":"253","author":"Davidson","year":"1987","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/S1734-1140(12)70740-5","article-title":"Exendin-4 reduces glycemia by increasing liver glucokinase activity: an insulin independent effect","volume":"64","author":"Dhanesha","year":"2012","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0085","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0006-2952(00)00579-7","article-title":"Specific desensitization of sulfonylurea- but not imidazoline-induced insulin release after prolonged tolbutamide exposure","volume":"61","author":"McClenaghan","year":"2001","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0090","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3390\/ijms25010571","article-title":"New-generation Glucokinase activators: potential game-changers in type 2 diabetes treatment","volume":"25","author":"Haddad","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0095","doi-asserted-by":"crossref","first-page":"S394","DOI":"10.2337\/diabetes.51.2007.S394","article-title":"Regulation of pancreatic beta-cell glucokinase: from basics to therapeutics","volume":"51","author":"Matschinsky","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0100","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.tem.2022.12.007","article-title":"Glucokinase activity in diabetes: too much of a good thing?","volume":"34","author":"Ashcroft","year":"2023","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0105","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ab.2011.08.037","article-title":"An enzymatic colorimetric assay for glucose-6-phosphate","volume":"419","author":"Zhu","year":"2011","journal-title":"Anal Biochem"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0293888","article-title":"Determination of progressive stages of type 2 diabetes in a 45% high-fat diet-fed C57BL\/6J mouse model is achieved by utilizing both fasting blood glucose levels and a 2-hour oral glucose tolerance test","volume":"18","author":"Nguyen-Phuong","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0115","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0092-8674(00)81294-5","article-title":"Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db\/db mice","volume":"84","author":"Chen","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0021-9150(97)00165-2","article-title":"C57BL\/6 mice fed high fat diets as models for diabetes-accelerated atherosclerosis","volume":"136","author":"Schreyer","year":"1998","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0125","doi-asserted-by":"crossref","unstructured":"Furman BL. Streptozotocin-induced diabetic models in mice and rats. Curr Protoc Pharmacol 2015;70:5.47.1\u20135.47.20. doi:https:\/\/doi.org\/10.1002\/0471141755.ph0547s70.","DOI":"10.1002\/0471141755.ph0547s70"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0130","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1476-5381.2012.02184.x","article-title":"Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans","volume":"168","author":"De Ceuninck","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0135","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2024-004291","article-title":"Glucokinase activators and imeglimin: new weaponry in the armamentarium against type 2 diabetes","volume":"12","author":"Sj\u00f6holm","year":"2024","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0140","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41591-018-0159-7","article-title":"Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase","volume":"24","author":"Hunter","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0145","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1074\/jbc.RA120.012533","article-title":"Metformin lowers glucose 6-phosphate in hepatocytes by activation of glycolysis downstream of glucose phosphorylation","volume":"295","author":"Moonira","year":"2020","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0150","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41591-022-01803-5","article-title":"Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"28","author":"Yang","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0155","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc11-1200","article-title":"Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes","volume":"34","author":"Meininger","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0160","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.2337\/db07-1807","article-title":"The common P446L polymorphism in GCKR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective general French population","volume":"57","author":"Vaxillaire","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0165","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s00125-011-2439-3","article-title":"Chronic treatment with a glucokinase activator delays the onset of hyperglycaemia and preserves beta cell mass in the Zucker diabetic fatty rat","volume":"55","author":"Futamura","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0170","doi-asserted-by":"crossref","unstructured":"RANDLE PJ, GARLAND PB, HALES CN, NEWSHOLME EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet (London, England). 1963;Vol. 1(7285):785\u2013789. doi:https:\/\/doi.org\/10.1016\/s0140-6736(63)91500-9.","DOI":"10.1016\/S0140-6736(63)91500-9"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0175","doi-asserted-by":"crossref","first-page":"960","DOI":"10.2337\/dc20-2684","article-title":"The SimpliciT1 study: a randomized, double-blind, placebo-controlled phase 1b\/2 adaptive study of TTP399, a Hepatoselective Glucokinase activator, for adjunctive treatment of type 1 diabetes","volume":"44","author":"Klein","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0180","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12933-024-02321-z","article-title":"Impaired GK-GKRP interaction rather than direct GK activation worsens lipid profiles and contributes to long-term complications: a Mendelian randomization study","volume":"23","author":"Wang","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0185","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s001250051247","article-title":"ATP-sensitive K+ channels and insulin secretion: their role in health and disease","volume":"42","author":"Ashcroft","year":"1999","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0190","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1464-5491.2007.02078.x","article-title":"Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with type 2 diabetes in UK primary care","volume":"24","author":"Cook","year":"2007","journal-title":"Diabet Med"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0195","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ejphar.2010.04.054","article-title":"A small-molecule glucokinase activator lowers blood glucose in the sulfonylurea-desensitized rat","volume":"640","author":"Ohyama","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0200","article-title":"Repair of diverse diabetic defects of \u03b2-cells in man and mouse by pharmacological glucokinase activation","volume":"14 Suppl 3(0 3):109-119","author":"Doliba","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0205","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/cpdd.276","article-title":"Pharmacokinetic and Pharmacodynamic drug interaction study of Piragliatin, a Glucokinase activator, and glyburide, a sulfonylurea, in type 2 diabetic patients","volume":"5","author":"Zhai","year":"2016","journal-title":"Clin Pharmacol drug Dev"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0210","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.2337\/diabetes.47.9.1392","article-title":"Expression of glucokinase in cultured human muscle cells confers insulin-independent and glucose concentration-dependent increases in glucose disposal and storage","volume":"47","author":"Baqu\u00e9","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2025.108977_bb0215","first-page":"185","volume":"174","author":"Bell","year":"2006","journal-title":"Do sulfonylurea drugs increase the risk of cardiac events? C Can Med Assoc J = J l\u2019Association medicale Can"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872725000303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872725000303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:47:40Z","timestamp":1761353260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872725000303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1056872725000303"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.108977","relation":{},"ISSN":["1056-8727"],"issn-type":[{"type":"print","value":"1056-8727"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological effect of ZYGK1, a novel glucokinase activator, in hyperglycemic and sulfonylurea-resistant type 2 diabetes in mice models","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.108977","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108977"}}